This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Medical Practice, Other  • Oncology  • Colon Cancer  • Alert me on articles by topic  Social Bookmarking   What's this?

Has It Influenced Clinical Practice?

Eric Van Cutsem, MD, PhD; Frederico Costa, MD

JAMA. 2005;294:2758-2760.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Colon cancer is a common malignancy in economically developed countries, particularly in North America, Europe, and Australia, and is one of the leading causes of cancer-related deaths in the Western world.^1-3 Every year, colorectal cancer is responsible for an estimated 400 000 deaths worldwide.^1-3

Among patients with colon cancer, 70% present with apparently localized disease. In these patients, surgery can be curative, but relapses after complete resection are frequent. Colon cancer is not uniformly fatal and there are large differences in survival depending on the stage of the disease at diagnosis. The pathological stage is currently the most important determinant of prognosis. The classification system described by Dukes in 1930 is still widely used, but it no longer fulfills the requirements of modern tumor staging because it does not take into account distant metastases, number of lymph nodes involved, and carcinomas limited to . . . [Full Text of this Article]

Author Affiliations: Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium (Dr Van Cutsem) and Centro de Oncologia, Hospital Sírio Libanês, São Paulo, Brazil (Dr Costa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation
J. Milburn Jessup, Andrew Stewart, Frederick L. Greene, and Bruce D. Minsky
JAMA. 2005;294(21):2703-2711.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Van Cutsem et al.
JCO 2009;27:3117-3125.
ABSTRACT | FULL TEXT